Meeting
2015 Genitourinary Cancers Symposium
HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
Authors
Jason W.D. Hearn
Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Jason W.D. Hearn , Ghada AbuAli , Cristina Magi-Galluzzi , Chandana A. Reddy , Kai-Hsiung Chang , Eric A. Klein , Nima Sharifi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 156)
DOI
10.1200/jco.2015.33.7_suppl.156
Abstract #
156
Poster Bd #
G18
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
First Author: Jason W.D. Hearn
Poster
2015 ASCO Annual Meeting
HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
First Author: Jason W.D. Hearn
Poster
2019 ASCO Annual Meeting
HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.
First Author: Jason W.D. Hearn
Poster
2013 Genitourinary Cancers Symposium
Adjuvant versus neoadjuvant androgen deprivation with radiation therapy for prostate cancer: Does sequencing matter?
First Author: Michael A. Weller